Jeffrey Almond | Former VP Discovery R&D, Sanofi & Visiting Professor
University of Oxford - Oxford Vaccine Group

Pre-Congress Workshops - Monday 13th October @ 10:00

Platform Technologies Workshop [AM1]

Jeffrey Almond, Former VP Discovery R&D, Sanofi & Visiting Professor, University of Oxford - Oxford Vaccine Group

Robbert Van der Most, CEO, Vaxxcellence

RAJESHWARI ADHISESHAN, senior program officer, Bill and melinda gates foundation

×

RAJESHWARI ADHISESHAN / Platform Technologies Workshop [AM1]

RAJESHWARI ADHISESHAN, senior program officer,
Bill and melinda gates foundation

Dr. Rajeshwari Adhiseshan is a Senior Program Officer at the Bill & Melinda Gates Foundation, where she plays a pivotal role in global health initiatives, particularly in the vaccine development sector. With a robust background in pharmacy and a PhD from Pune University, Dr. Rajeshwari has...

CloseMore

Kayvon Modjarrad, Executive Director, Viral Vaccines, Pfizer

Session led by: intravacc

Session led by: adaptvac

Day 2 - Wednesday 15th October @ 14:15

Panel: Why has flu vaccine efficacy stalled and how do we fix it?

Jerald Sadoff, Chief Medical Officer, Centivax

×

Jerald Sadoff / Panel: Why has flu vaccine efficacy stalled and how do we fix it?

Jerald Sadoff, Chief Medical Officer,
Centivax

Dr. Jerald Sadoff, M.D. as Chief Medical Officer with immediate effect. Dr. Sadoff has more than fifty years of experience in vaccine development. He has overseen or played a key role in the approval of more vaccines than any other currently active vaccine developer, including vaccines against...

CloseMore

Jeffrey Almond, Former VP Discovery R&D, Sanofi & Visiting Professor, University of Oxford - Oxford Vaccine Group

Day 3 - Thursday 16th October @ 12:30

Strategic Partnerships in Vaccine Development: Platforms vs. Products

• How are biopharma partnerships evolving?
• Evaluating technology-led vs. product-led partnership models
• Bridging academic immunology discoveries to biotech commercialisation
• Balancing partner interests in multi-stakeholder vaccine projects
• Structuring deals and best practices in securing platform technology partnerships